Insider Selling: Maze Therapeutics (NASDAQ:MAZE) Insider Sells $206,850.00 in Stock

Key Points

• Maze Therapeutics insider Atul Dandekar sold 7,500 shares for $206,850 under a pre-arranged Rule 10b5-1 plan, reducing his position by 22.22% to 26,250 shares.
• Dandekar has also sold 7,500 shares each in June and July, making this the third reported sale in recent months.
• MAZE recently traded at $26.57, while analysts maintain an overall “Buy” rating with an average price target of $66.00, despite mixed individual ratings.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of the firm's stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $27.58, for a total transaction of $206,850.00. Following the sale, the insider owned 26,250 shares of the company's stock, valued at approximately $723,975. The trade was a 22.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.34, for a total value of $205,050.00.
• On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $28.02, for a total value of $210,150.00.

Maze Therapeutics Stock Performance

NASDAQ MAZE traded down $0.87 on Monday, hitting $26.57. 493,470 shares of the stock traded hands, compared to its average volume of 643,897. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The business's fifty day moving average is $28.74 and its two-hundred day moving average is $31.79. Maze Therapeutics, Inc. has a 12 month low of $13.89 and a 12 month high of $53.65. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -10.54 and a beta of 2.22.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts' consensus estimates of ($0.76). As a group, equities analysts anticipate that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Analyst Ratings Changes

MAZE has been the topic of several recent research reports. TD Cowen raised shares of Maze Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. Weiss Ratings reissued a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen cut shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Finally, BTIG Research reaffirmed a "buy" rating and issued a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, August 12th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $66.00.

Institutional Trading of Maze Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada increased its holdings in Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after acquiring an additional 363 shares during the period. Ameritas Investment Partners Inc. lifted its stake in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock worth $42,000 after purchasing an additional 738 shares in the last quarter. California State Teachers Retirement System boosted its holdings in Maze Therapeutics by 138.0% in the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company's stock valued at $55,000 after purchasing an additional 766 shares during the period. Police & Firemen s Retirement System of New Jersey boosted its holdings in Maze Therapeutics by 18.5% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company's stock valued at $247,000 after purchasing an additional 931 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Maze Therapeutics by 23.0% during the 3rd quarter. Legal & General Group Plc now owns 5,219 shares of the company's stock valued at $135,000 after purchasing an additional 977 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source